gonadotropin-releasing hormone agonist (GnRH analog)
Jump to navigation
Jump to search
Indications
- hormonal treatment of prostate cancer
- ovarian cancer
- breast cancer
- endometriosis
- precocious puberty[3]
Adverse effects
- may cause an initial surge in testosterone production before lowering testosterone levels
- increase in the risk of diabetes[1][2]
- increase in the risk of cardiovascular disease[1][2]
- osteoporosis & bone fractures[4]
Mechanism of action
- dminishes testosterone secretion by Leydig cells of the testis by down-regulating GnRH receptors
- down-regulating GnRH receptors affects LH & FSH release from the anterior pituitary
- diminished LH diminished strimulus for testosterone secretion
More general terms
More specific terms
- buserelin (Suprecur)
- deslorelin (Suprelorin, Somagard, Tryptal, Ovuplant)
- goserelin (Zoladex)
- leuprolide; leuprorelin (Lupron, Eligard)
- Lutrepulse (Relisorm, Factrel, GnRH, GnRH1)
- nafarelin (Synarel)
- triptorelin (Trelstar LA)
Additional terms
- gonadotropin-releasing hormone [GNRH] receptor
- gonadotropin-releasing hormone/factor; gonadoliberin; LH/FSH-releasing hormone (GnRH, LHRH)
References
- ↑ 1.0 1.1 1.2 FDA MedWatch 05/03/2010 GnRH Agonists: Safety Review of Drug Class Used to Treat Prostate Cancer http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm210576.htm
- ↑ 2.0 2.1 2.2 FDA MedWatch 10/20/2010 GnRH Agonists: Label Change - Increased Risk of Diabetes and Cardiovascular Disease (Update) http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm230359.htm
- ↑ 3.0 3.1 Deprecated Reference
- ↑ 4.0 4.1 Smith MR, Lee WC, Brandman J et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005 Nov 1; 23:7897 PMID: https://www.ncbi.nlm.nih.gov/pubmed/162580